Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip Scheltens

Showing results (121-130 of 953) with videos related to

Pageof 96
Sort By:
Cognitive and Behavioral Neurology : Official Journal of the Society for Behavioral and Cognitive Neurology|March 6, 2020
Effectiveness of Pharmacological Interventions for Symptoms of Behavioral Variant Frontotemporal Dementia: A Systematic ReviewCalvin Trieu, Flora Gossink, Max L Stek, et al.
Journal of the American Geriatrics Society|June 7, 2005
Low vitamin B6 levels are associated with white matter lesions in Alzheimer's diseaseCees Mulder, Philip Scheltens, Frederik Barkhof, et al.
Alzheimer'S & Dementia (New York, N. Y.)|November 11, 2017
The effect of diagnostic criteria on outcome measures in preclinical and prodromal Alzheimer's disease: Implications for trial designDaniela Bertens, Betty M Tijms, Lisa Vermunt, et al.
Plos Computational Biology|August 24, 2012
Activity dependent degeneration explains hub vulnerability in Alzheimer's diseaseWillem de Haan, Katherine Mott, Elisabeth C W van Straaten, et al.
Alzheimer'S Research & Therapy|October 12, 2019
Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodiesInger van Steenoven, Wiesje M van der Flier, Philip Scheltens, et al.
Dementia and Geriatric Cognitive Disorders Extra|October 20, 2022
Clinical Features of Patients with Alzheimer's Disease and a History of Traumatic Brain InjurySuzan van Amerongen, Dewi K Caton, Yolande A L Pijnenburg, et al.
Alzheimer'S Research & Therapy|May 28, 2021
A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer's diseaseNiels D Prins, John E Harrison, Hui-May Chu, et al.
Neuroimage|August 1, 2009
Simplified parametric methods for [18F]FDDNP studiesMaqsood Yaqub, Nelleke Tolboom, Bart N M van Berckel, et al.
Nederlands Tijdschrift Voor Geneeskunde|October 17, 2013
[The behavioural variant of frontotemporal dementia: a challenging diagnosis]Flora Gossink, Annemiek Dols, Cora J Kerssens, et al.
Brain Communications|December 30, 2020
Grey matter network trajectories across the Alzheimer's disease continuum and relation to cognitionEllen Dicks, Lisa Vermunt, Wiesje M van der Flier, et al.
Pageof 96

Showing results (121-130 of 953) with videos related to

Sort By:
Pageof 96
Cognitive and Behavioral Neurology : Official Journal of the Society for Behavioral and Cognitive Neurology|March 6, 2020
Effectiveness of Pharmacological Interventions for Symptoms of Behavioral Variant Frontotemporal Dementia: A Systematic ReviewCalvin Trieu, Flora Gossink, Max L Stek, et al.
Journal of the American Geriatrics Society|June 7, 2005
Low vitamin B6 levels are associated with white matter lesions in Alzheimer's diseaseCees Mulder, Philip Scheltens, Frederik Barkhof, et al.
Alzheimer'S & Dementia (New York, N. Y.)|November 11, 2017
The effect of diagnostic criteria on outcome measures in preclinical and prodromal Alzheimer's disease: Implications for trial designDaniela Bertens, Betty M Tijms, Lisa Vermunt, et al.
Plos Computational Biology|August 24, 2012
Activity dependent degeneration explains hub vulnerability in Alzheimer's diseaseWillem de Haan, Katherine Mott, Elisabeth C W van Straaten, et al.
Alzheimer'S Research & Therapy|October 12, 2019
Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodiesInger van Steenoven, Wiesje M van der Flier, Philip Scheltens, et al.
Dementia and Geriatric Cognitive Disorders Extra|October 20, 2022
Clinical Features of Patients with Alzheimer's Disease and a History of Traumatic Brain InjurySuzan van Amerongen, Dewi K Caton, Yolande A L Pijnenburg, et al.
Alzheimer'S Research & Therapy|May 28, 2021
A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer's diseaseNiels D Prins, John E Harrison, Hui-May Chu, et al.
Neuroimage|August 1, 2009
Simplified parametric methods for [18F]FDDNP studiesMaqsood Yaqub, Nelleke Tolboom, Bart N M van Berckel, et al.
Nederlands Tijdschrift Voor Geneeskunde|October 17, 2013
[The behavioural variant of frontotemporal dementia: a challenging diagnosis]Flora Gossink, Annemiek Dols, Cora J Kerssens, et al.
Brain Communications|December 30, 2020
Grey matter network trajectories across the Alzheimer's disease continuum and relation to cognitionEllen Dicks, Lisa Vermunt, Wiesje M van der Flier, et al.
Pageof 96